Publications

Mosquera J-M, Perner S, Genega EM, Sanda M, Hofer MD, Mertz KD, Paris PL, Simko J, Bismar TA, Ayala G et al..  2008.  Characterization of TMPRSS2-ERG fusion high-grade prostatic intraepithelial neoplasia and potential clinical implications.. Clin Cancer Res. 14(11):3380-5.

Mosquera JMiguel, Beltran H, Park K, MacDonald TY, Robinson BD, Tagawa ST, Perner S, Bismar TA, Erbersdobler A, Dhir, iv R et al..  2013.  Concurrent AURKA and MYCN gene amplifications are harbingers of lethal treatment-related neuroendocrine prostate cancer.. Neoplasia. 15(1):1-10.

Mosquera J-M, Varma S, Pauli C, MacDonald TY, Yashinskie JJ, Varga Z, Sboner A, Moch H, Rubin MA, Shin SJ.  2015.  MAGI3-AKT3 fusion in breast cancer amended.. Nature. 520(7547):E11-2.

Mosquera J-M, Mehra R, Regan MM, Perner S, Genega EM, Bueti G, Shah RB, Gaston S, Tomlins SA, Wei JT et al..  2009.  Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States.. Clin Cancer Res. 15(14):4706-11.

Mertz KD, Demichelis F, Kim R, Schraml P, Storz M, Diener P-A, Moch H, Rubin MA.  2007.  Automated immunofluorescence analysis defines microvessel area as a prognostic parameter in clear cell renal cell cancer.. Hum Pathol. 38(10):1454-62.

Mertz KD, Setlur SR, Dhanasekaran SM, Demichelis F, Perner S, Tomlins S, Tchinda J, Laxman B, Vessella RL, Beroukhim R et al..  2007.  Molecular characterization of TMPRSS2-ERG gene fusion in the NCI-H660 prostate cancer cell line: a new perspective for an old model.. Neoplasia. 9(3):200-6.

Mertz KD, Demichelis F, Sboner A, Hirsch MS, Dal Cin P, Struckmann K, Storz M, Scherrer S, Schmid DM, Strebel RT et al..  2008.  Association of cytokeratin 7 and 19 expression with genomic stability and favorable prognosis in clear cell renal cell cancer.. Int J Cancer. 123(3):569-76.

Mateo J, Carreira S, Sandhu S, Miranda S, Mossop H, Perez-Lopez R, Rodrigues DNava, Robinson D, Omlin A, Tunariu N et al..  2015.  DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.. N Engl J Med. 373(18):1697-708.

Mateo J, Boysen G, Barbieri CE, Bryant HE, Castro E, Nelson PS, Olmos D, Pritchard CC, Rubin MA, de Bono JS.  2016.  DNA Repair in Prostate Cancer: Biology and Clinical Implications.. Eur Urol.

Lin P-C, Chiu Y-L, Banerjee S, Park K, Mosquera JMiguel, Giannopoulou E, Alves P, Tewari AK, Gerstein MB, Beltran H et al..  2013.  Epigenetic repression of miR-31 disrupts androgen receptor homeostasis and contributes to prostate cancer progression.. Cancer Res. 73(3):1232-44.

Kumar-Sinha C, Shah RB, Laxman B, Tomlins SA, Harwood J, Schmitz W, Conzelmann E, Sanda MG, Wei JT, Rubin MA et al..  2004.  Elevated alpha-methylacyl-CoA racemase enzymatic activity in prostate cancer.. Am J Pathol. 164(3):787-93.

Kim R, Demichelis F, Tang J, Riva A, Shen R, Gibbs DF, Mahavishno V, Chinnaiyan AM, Rubin MA.  2005.  Internet-based Profiler system as integrative framework to support translational research.. BMC Bioinformatics. 6:304.

Khurana E, Fu Y, Chakravarty D, Demichelis F, Rubin MA, Gerstein M.  2016.  Role of non-coding sequence variants in cancer.. Nat Rev Genet. 17(2):93-108.

Kelly KA, Setlur SR, Ross R, Anbazhagan R, Waterman P, Rubin MA, Weissleder R.  2008.  Detection of early prostate cancer using a hepsin-targeted imaging agent.. Cancer Res. 68(7):2286-91.

Imielinski M, Rubin MA.  2017.  Prostate cancer: Clinical hallmarks in whole cancer genomes.. Nat Rev Clin Oncol.

Hofer MD, Browne TJ, He L, Skotheim RI, Lothe RA, Rubin MA.  2005.  Identification of two molecular groups of seminomas by using expression and tissue microarrays.. Clin Cancer Res. 11(16):5722-9.

Hofer MD, Kuefer R, Maier C, Herkommer K, Perner S, Demichelis F, Paiss T, Vogel W, Rubin MA, Hoegel J.  2009.  Genome-wide linkage analysis of TMPRSS2-ERG fusion in familial prostate cancer.. Cancer Res. 69(2):640-6.

Hofer MD, Kuefer R, Varambally S, Li H, Ma J, Shapiro GI, Gschwend JE, Hautmann RE, Sanda MG, Giehl K et al..  2004.  The role of metastasis-associated protein 1 in prostate cancer progression.. Cancer Res. 64(3):825-9.

Hofer MD, Kuefer R, Huang W, Li H, Bismar TA, Perner S, Hautmann RE, Sanda MG, Gschwend JE, Rubin MA.  2006.  Prognostic factors in lymph node-positive prostate cancer.. Urology. 67(5):1016-21.

Hofer MD, Fecko A, Shen R, Setlur SR, Pienta KG, Tomlins SA, Chinnaiyan AM, Rubin MA.  2004.  Expression of the platelet-derived growth factor receptor in prostate cancer and treatment implications with tyrosine kinase inhibitors.. Neoplasia. 6(5):503-12.

Gillessen S, Omlin A, Attard G, de Bono JS, Efstathiou E, Fizazi K, Halabi S, Nelson PS, Sartor O, Smith MR et al..  2015.  Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015.. Ann Oncol. 26(8):1589-604.

Gillessen S, Omlin A, Attard G, de Bono JS, Efstathiou E, Fizazi K, Halabi S, Nelson PS, Sartor O, Smith MR et al..  2016.  Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015.. Ann Oncol.

Gayvert KM, Dardenne E, Cheung C, Boland MRegina, Lorberbaum T, Wanjala J, Chen Y, Rubin MA, Tatonetti NP, Rickman DS et al..  2016.  A Computational Drug Repositioning Approach for Targeting Oncogenic Transcription Factors.. Cell Rep. 15(11):2348-56.

Garraway LA, Widlund HR, Rubin MA, Getz G, Berger AJ, Ramaswamy S, Beroukhim R, Milner DA, Granter SR, Du J et al..  2005.  Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma.. Nature. 436(7047):117-22.

Fontugne J, Davis K, Palanisamy N, Udager A, Mehra R, McDaniel AS, Siddiqui J, Rubin MA, Mosquera JMiguel, Tomlins SA.  2016.  Clonal evaluation of prostate cancer foci in biopsies with discontinuous tumor involvement by dual ERG/SPINK1 immunohistochemistry.. Mod Pathol. 29(2):157-65.